Wegovy Pill: What Oral Semaglutide for Obesity Is
Wegovy pill explained: FDA-approved oral semaglutide for obesity, how it compares with injectable Wegovy and Rybelsus, and side effects. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
The Wegovy pill is a once-daily oral form of semaglutide that the FDA approved in December 2025 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It is the same active ingredient as injectable Wegovy and as Rybelsus (the diabetes tablet), but at a higher strength for obesity. In its phase 3 trial, average weight loss over 64 weeks was about 16.6% versus 2.7% on placebo. Side effects follow the GLP-1 pattern — mainly nausea, vomiting, diarrhoea and constipation — and the pill carries the same semaglutide label warnings. Like Rybelsus, it has fasting-style administration instructions; follow the label and prescriber. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What the OASIS 4 trial showed
64 weeks, 307 adults with obesity or overweight and a related condition, without diabetes (NEJM 2025). Last reviewed October 15, 2026.
| Outcome | Wegovy pill | Placebo |
|---|---|---|
| Average weight change, all participants | -13.6% | -2.2% |
| Average weight change, if taken as directed | -16.6% | -2.7% |
| Any GI side effect | 74% | 42% |
| Nausea | About 47% | About 19% |
| Vomiting | About 31% | About 6% |
| Stopped because of GI side effects | 3.4% | 2.0% |
Pill vs injection vs other pills
Novo Nordisk describes the weight loss as similar to injectable Wegovy, but there is no head-to-head trial. The pill also carries Wegovy's cardiovascular risk-reduction indication. Its main practical difference is the daily routine: it must be taken on an empty stomach with a small sip of water, and you have to wait before eating, drinking or taking other pills. Foundayo has no such rules. Comparison: all GLP-1 pills, Foundayo vs Wegovy pill. Not available in Canada: Wegovy pill in Canada.
What users report here
No published confession is tagged to the Wegovy pill yet. Semaglutide injection users describe GI trouble early (#298), hair shedding (#43) and quick regain after stopping (#57); the pill contains the same molecule. Browse semaglutide reports.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- When was the Wegovy pill approved?
- The FDA approved it on December 22, 2025, and it launched in the US in January 2026.
- What are the Wegovy pill's side effects?
- Mainly nausea, vomiting, diarrhoea and constipation, peaking during dose escalation. In OASIS 4, 74% had a GI side effect vs 42% on placebo; few stopped because of them.
- Is the Wegovy pill available in Canada?
- Not as of October 15, 2026.
- Is there a Wegovy pill?
- Yes. The FDA approved an oral semaglutide tablet under the Wegovy brand for weight management in December 2025.
- Is the Wegovy pill the same as Rybelsus?
- Same molecule (semaglutide). Rybelsus is labelled for type 2 diabetes; the Wegovy pill is a higher-strength tablet labelled for weight management.
- Does the Wegovy pill work as well as the injection?
- Trial averages were broadly similar in magnitude, but they come from separate trials. A clinician can explain which form suits an individual.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
- Is the Wegovy pill as effective as the injection?
- Average weight loss in the pill's trial was somewhat lower than in the injection's trials, though the trials were not head-to-head. Individual results vary.
- Why do people stop Wegovy?
- Common reasons are gastrointestinal side effects, access problems and reaching a goal. Trials show most people regain weight after stopping.
Sources
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.